title: The treatment of systemic lupus proliferative nephritis.
abstract: Lupus nephritis is one of the most common and serious complications of systemic lupus erythematosus (SLE) in childhood affecting more than 80% of patients. Treatment of this complication has undergone significant evolution in recent years. A series of randomized controlled trials has clarified the role of a variety of immunomodulating regimens including some novel biologic medications. This review touches on the major trials that have influenced practice and shaped current thinking about the treatment of proliferative lupus glomerulonephritis.
authors.affiliation: UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9063, USA, Marilynn.Punaro@UTSouthwestern.edu.
authors.forename: Marilynn G
authors.initials: MG
authors.lastname: Punaro
mesh_terms: D000963:Antimetabolites / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001688:Biological Products; D002648:Child; D017408:Guidelines as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008181:Lupus Nephritis / Q000188:drug therapy / Q000628:therapy*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010956:Plasmapheresis; D016032:Randomized Controlled Trials as Topic
chemical_list: D000963:Antimetabolites; D001688:Biological Products; D007155:Immunologic Factors; D009173:Mycophenolic Acid; D001379:Azathioprine